Voyager spells out its $92M IPO pitch as Wall Street sours on biotech

Gene therapy developer Voyager Therapeutics is angling for as much as $92 million in a planned IPO, braving choppy waters for biotech after a string of disappointing debuts for life sciences companies.

Source: www.fiercebiotech.com

---